Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 10/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256738 | 0.86 | KLK5 (0.51) | KLK7KLK5KMT2AL3MBTL1KDM1A | |
| SCHEMBL26878946 | 0.86 | KLK7 (0.47) | KLK7KLK5KMT2AL3MBTL1KDM1A | |
| SCHEMBL24256425 | 0.86 | KLK5 (0.51) | KLK7KLK5KMT2AL3MBTL1KDM1A | |
| SCHEMBL16211783 | 0.85 | SLC6A2 (0.47) | KLK7KLK5L3MBTL1SLC6A2BCHE | |
| SCHEMBL26879067 | 0.85 | KLK5 (0.50) | KLK7KLK5KMT2AL3MBTL1KDM1A | |
| SCHEMBL16211859 | 0.82 | KLK7 (0.46) | KLK7KLK5KMT2AL3MBTL1MAOB | |
| SCHEMBL14363001 | 0.82 | SLC6A2 (0.45) | KLK7KLK5L3MBTL1SLC6A2BCHE | |
| SCHEMBL29704756 | 0.81 | KLK7 (0.52) | KLK7KLK5KMT2AL3MBTL1KDM1A | |
| SCHEMBL25084107 | 0.78 | GAA (0.36) | KDM1AMAOB | |
| SCHEMBL402803 | 0.78 | SLC6A2 (0.43) | KLK7KLK5L3MBTL1SLC6A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991978-B1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F HOFFMANN LA ROCHE SA (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| WO-2014177060-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | KLK7 3008/4885KLK5 3145/4885KMT2A 2566/4885 |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | KLK7 3008/4885KLK5 3145/4885KMT2A 2566/4885 |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | KLK7 3008/4885KLK5 3145/4885KMT2A 2566/4885 |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | KLK7 3008/4885KLK5 3145/4885KMT2A 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.